QQ客服 官方微博 反馈留言

	Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer
	Wang, Shouzheng; Li, Junling
	2019
卷号	12页码:6535-6548
关键词	afatinib dacomitinib epidermal growth factor receptor non-small-cell lung cancer
ISSN号	1178-6930
DOI	10.2147/OTT.S198945
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6337444
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Wang, Shouzheng,Li, Junling. Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer[J],2019,12:6535-6548.
APA	Wang, Shouzheng,&Li, Junling.(2019).Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer.,12,6535-6548.
MLA	Wang, Shouzheng,et al."Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer".12(2019):6535-6548.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。